Brolucizumab-Dbll vs HLX04-O
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Brolucizumab-Dbll
Marketed by Novartis and partners
NCT05672979 · Phase 3 · status unknown
This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.
No aligned efficacy figure on record for this race.
HLX04-O
Developed by Essex Bio-Technology Limited under a licence from Shanghai Henlius Biotech
NCT04740671 · Phase 3 · completed
This randomized, double-blind Phase 3 trial assigned 410 people with wet age-related macular degeneration to intravitreal HLX04-O or the active comparator ranibizumab, with mean change in best-corrected visual acuity at Week 36 as its non-inferiority primary endpoint. Registry results are not posted; the sponsor reports that the primary and key secondary (Week 48) endpoints were met, with HLX04-O non-inferior to ranibizumab, without giving figures, so the size of the effect cannot be checked.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
Results for Age-Related Macular Degeneration
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Brolucizumab-Dbll: registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.
HLX04-O: no structured comparison results are available for Age-Related Macular Degeneration.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brolucizumab-Dbll's landscape · HLX04-O's landscape